Catalent, a leading drug contract manufacturing organization (CMO), has a $114 million expansion underway at its Bloomington, Indiana, production plant. First reported by Industrial Info in January 2019, the project launched late last year. The expansion adds 79,000 square feet of biological fill and finish capacity. When completed next year, it will help the company's alliance with Johnson & Johnson in production of an eventual COVID-19 vaccine.